Literature DB >> 30700953

The Burden of HIV/AIDS in Ethiopia from 1990 to 2016: Evidence from the Global Burden of Diseases 2016 Study.

Amare Deribew1,2, Sibhatu Biadgilign3, Kebede Deribe4,5, Tariku Dejene6, Gizachew Assefa Tessema7,8, Yohannes Adama Melaku9,10, Yihune Lakew11, Azmeraw T Amare12,13, Tolessa Bekele14, Semaw F Abera9,15,16, Muluken Dessalegn17, Andargachew Kumsa18, Yibeltal Assefa19, Scott D Glenn20, Tahvi Frank20, Austin Carter20, Awoke Misganaw20, Haidong Wang20.   

Abstract

BACKGROUND: The burden of HIV/AIDS in Ethiopia has not been comprehensively assessed over the last two decades. In this study, we used the 2016 Global Burden of Diseases, Injuries and Risk factors (GBD) data to analyze the incidence, prevalence, mortality and Disability-adjusted Life Years Lost (DALY) rates of Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome (HIV/AIDS) in Ethiopia over the last 26 years.
METHODS: The GBD 2016 used a wide range of data source for Ethiopia such as verbal autopsy (VA), surveys, reports of the Federal Ministry of Health and the United Nations (UN) and published scientific articles. The modified United Nations Programme on HIV/AIDS (UNAIDS) Spectrum model was used to estimate the incidence and mortality rates for HIV/AIDS.
RESULTS: In 2016, an estimated 36,990 new HIV infections (95% uncertainty interval [UI]: 8775-80262), 670,906 prevalent HIV cases (95% UI: 568,268-798,970) and 19,999 HIV deaths (95% UI: 16426-24412) occurred in Ethiopia. The HIV/AIDS incidence rate peaked in 1995 and declined by 6.3% annually for both sexes with a total reduction of 77% between 1990 and 2016. The annualized HIV/AIDS mortality rate reduction during 1990 to 2016 for both sexes was 0.4%.
CONCLUSIONS: Ethiopia has achieved the 50% reduction of the incidence rate of HIV/AIDS based on the Millennium Development Goals (MDGs) target. However, the decline in HIV/AIDS mortality rate has been comparatively slow. The country should strengthen the HIV/AIDS detection and treatment programs at community level to achieve its targets during the Sustainable Development Program (SDGs)-era.

Entities:  

Keywords:  Burden; Ethiopia; GBD; HIV/AIDS

Mesh:

Year:  2019        PMID: 30700953      PMCID: PMC6341438          DOI: 10.4314/ejhs.v29i1.7

Source DB:  PubMed          Journal:  Ethiop J Health Sci        ISSN: 1029-1857


Introduction

The global momentum of HIV/AIDS interventions has been intensified since the launch of the Millennium Development Goals (MDG) that aimed to reduce the incidence of HIV/AIDS by 50% by 2015 (1,2). However, HIV/AIDS is still the major public health problem globally. In 2015, there were about 1.1 million HIV/AIDS deaths, 2.1 million new HIV infections and a total of 36.7 million people who had HIV in their blood. Sub-Saharan Africa is the most affected region, with 25.6 million people living with HIV in 2015 (3). The burden of HIV/AIDS remains high in Ethiopia despite a considerable scaleup of comprehensive HIV/AIDS interventions during the MDG period. In 2016, there were about 718,500 people living with HIV/AIDS (4). The 2017 UNAID global AIDS report revealed that the number of new HIV infections in Ethiopia were higher in 2016 than in 2010 (5). The reemergence of HIV/AIDS in Ethiopia could be due to the low coverage of high impact interventions. For instance, the 59% coverage of Highly Active Antiretroviral Treatment (HAART) in Ethiopia is below the regional average, and only 67% of Ethiopians know their HIV status (5). Achievement of the HIV/AIDS related Sustainable Development Goals (SDGs) in Ethiopia requires concerted efforts of scaling up comprehensive HIV/AIDS interventions and a robust health management information system (HMIS) that helps to evaluate the burden of HIV/AIDS. Over the last two decades, the prevalence, incidence and number of AIDS deaths have been estimated in Ethiopia using the Antenatal Care (ANC) based sentinel surveillance system (6). In this study, we used the Global Burden of Diseases (GBD) 2016 data (7–10) to assess the burden (prevalence, incidence, mortality and Disability-adjusted Life Years Lost rates) of HIV/AIDS over the last 26 years. There are several reasons to use the GBD data: First, it employs rigorous methods to estimate rates including DALY as described in the methods section of this article; second, GBD uses a standardized methodology that is essential to compare the performance of Ethiopia with that of other countries in terms of achieving the HIV/AIDS related targets. The study provides reliable information on the achievement of HIV-related targets of the MDG. It also helps decision makers to allocate resources based on the burden of HIV/AIDS. Lastly, the study will serve as a baseline indicator to track progresses during the SDG era.

Methods

The Ethiopian population (approximately 100 million) is the second largest in Africa with diverse population mix and unique cultural heritages (11). The GBD 2016 data were used to analyze the incidence, prevalence and mortality rates of HIV/AIDS. The GBD 2016 utilizes comprehensive sources of data and rigorous analysis to estimate trends of cause-specific mortality rates and risk factors for 188 countries (7,8,10,12). Data sources: The study employed a mathematical modeling using the GBD data. The GBD 2016 used a wide range of HIV/AIDS data for Ethiopia (http://ghdx.healthdata.org/). The key sources of data for HIV/AIDS include verbal autopsy, Demographic and Health Surveys (DHS) and data reported by the Ministry of Health to UNAIDS via the Spectrum software (12,13). In addition, cohort data from throughout sub-Saharan Africa was used to estimate input parameters to the Ethiopian HIV epidemic model. Analysis strategies: The GBD uses recoded versions of the Epidemic and Projection Package (EPP) and Spectrum model which allow for draw-level linkage between HIV estimates and all-cause mortality estimates (14,15). The GBD populations and vital rates are used as inputs to the population projections within EPP and Spectrum. HIV mortality and disease progression parameters estimates differ from UNAIDS due to different data sources and modelling strategies. Within Spectrum, GBD methods included a novel approach to allocating ART across CD4 count groups with coverage distributions estimated using data from systematic review and survey. Estimates of HIV-specific mortality from the life table process are averaged with mortality rates coming from the epidemic model and, in order to preserve prevalence estimates, new HIV infections are back-calculated to align with updated mortality (10). Causes of death by age groups, sex and year for other diseases were measured using CODEm. A detailed description of CODEm is reported elsewhere (12,16–18). In summary, CODEm tests and selects the best-performing model from a wide range of models such as mixed-effects linear models and spatiotemporal Gaussian process regression (STGPR) models in predicting mortality rates and cause fractions (12). Quality assurance: The GBD 2016 analysis uses reliable data including DHS, published articles and ministry of health reports. Unpublished data from other sources were excluded. Ethical approval: The study used secondary data from the GBD 2016. The GBD 2016 data are anonymous and available and can be accessed at the GBD website (http://vizhub.healthdata.org/gbd-compare/).

Results

Incidence: In 2016, there were an estimated 36,990 new HIV infections for all ages and sexes (95% UI: 8775-80,262) in Ethiopia. The age-standardised incidence rate declined from 178/100,000 to 40/100,000 between 1990 and 2016 with a total reduction of 77%. HIV incidence rate peaked in 1995, declined steadily till 2005 and have become stable since 2005. The annualized rate of change (ARC) for the HIV incidence rate during 1990 and 2016 was −6.3% (Figure 1).
Figure 1

Number of New HIV infection (A) and HIV/AIDS incidence rate (B) by sex between 1990 and 2016.

Number of New HIV infection (A) and HIV/AIDS incidence rate (B) by sex between 1990 and 2016. Prevalence: An estimated 670,906 (95% UI: 568, 268–798, 970) people living with HIV were registered in 2016. The number of females with HIV/AIDS (385,642) was higher than the number of males (285,263) with HIV/AIDS in 2016. The age-standardised HIV prevalence rate peaked in 2000 (1984 cases/100,000), declined steadily until 2010 and has remain stable thereafter (Figure 2).
Figure 2

Number of people with HIV/Prevalence (A) and HIV/AIDS prevalence rate (B) by sex between 1990 and 2016

Number of people with HIV/Prevalence (A) and HIV/AIDS prevalence rate (B) by sex between 1990 and 2016 Mortality: In 2016, nearly 20,000 AIDS related deaths (95% UI: 16,426–24,412) occurred in Ethiopia. AIDS mortality rate peaked in 2005 (150/100,000). The age-standardised AIDS mortality rate declined very fast after 2005 and reach 24/100,000 in 2016 (Table 1). In 2016, the number of HIV/AIDS deaths and mortality rate was highest in the age group of 35–54 years, and males and females had similar mortality patterns (Figure 3).
Table 1

Number of deaths and mortality rate of HIV/AIDS in Ethiopia, both sex between 1990 and 2016

Year#Deaths95%UIRate/100,00095%UI
1990801045771375722.612.739.3
199533603229594761181.655.1116.0
2000673114919987753145.8106.4188.1
2005784946414693937149.8125.0175.1
201042288361694948364.354.575.6
201521785176282655227.221.934.3
201619999164262441224.219.829.8
Figure 3

Number of HIV/AIDS deaths (A) and HIV/AIDS mortality rate (B) by age and sex in Ethiopia in 2016

Number of deaths and mortality rate of HIV/AIDS in Ethiopia, both sex between 1990 and 2016 Number of HIV/AIDS deaths (A) and HIV/AIDS mortality rate (B) by age and sex in Ethiopia in 2016 DALY: An estimated 1.1 million (95% UI: 0.9 million-1.4 million) AIDS related DALY were registered in Ethiopia in 2016. Age-standardised AIDS DALY rate progressively increased between 1990 and 2005 and declined steadily since 2005 (Table 2).
Table 2

Number of DALY and DALY rate of HIV/AIDS in Ethiopia, both sex between 1990 and 2016

Year#DALY95% UIDALY95%UI
Rate/100,000
19904434682713017391291119.9671.21889.4
19951830619129284725654903952.32729.05542.1
20003621372270881446976876958.25130.49007.0
20054166924335960350196287055.95726.28407.5
20102367533201511128076933235.42792.23730.8
20151245178101048715050401401.01147.71658.7
2016114596294115014197921253.81041.51510.5
Number of DALY and DALY rate of HIV/AIDS in Ethiopia, both sex between 1990 and 2016

Discussion

Ethiopia showed remarkable progress in reducing the burden and reversing epidemic of HIV/AIDS in the last two decades. The country reduced the incidence of HIV/AIDS by 77%, which surpasses the MDG target of 50% incidence reduction (2). Other reports of the United Nations (UN) also show that Ethiopia has achieved most of the MDG targets related to HIV (19,20). However, there were very few studies that evaluated the burden of HIV/AIDS in Ethiopia. Hladik and colleagues reported that the prevalence of HIV/AIDS in Ethiopia was below 2% in 1990 and reached 4.4% in 2003 and remained stable until 2008 (21). In the same study, the incidence rate of HIV/AIDS was 0.5% and 3.3% in rural and urban areas respectively in 1990. The modeled adult HIV incidence by the same authors for whole Ethiopia showed a steady but slow growth to 0.68% in 2003 and stabilized for the years 2004–08 (21). This study using GBD data reveals that prevalence reaches its peak (2%) in 2000 and declines to 1% in 2010 and remained stable since then. In addition, our study shows that the incidence rate steadily increased until 1995(0.3%) and dramatically declined to 0.04% in 2005 and remained stable. The prevalence and incidence rates in the GBD estimates are lower than the estimates made by Hladik et al. (21). Our estimates of the number of AIDS deaths (n=20,000) and number of people living with HIV (n=670,906) in 2016 were different from the estimates of Ethiopian Public Health Institute (EPHI) and UNAIDS report (5,22). Although the EPHI mortality estimate in 2016(n=19, 743) is nearly the same as our estimate, GBD underestimates the number of people living with HIV compared to the EPHI estimate in the same year (n=718,500). On the other hand, the prevalence of HIV/AIDS in 2015 (1.21%) and 2016 (1.18%) estimated by the Ethiopian Public Health Institute (EPHI) is similar to the GBD estimate (22). The differences in GBD estimates and other methods that use EPP could be due to the methodological differences. GBD has modified the EPP and the Spectrum in several ways as discussed in the previous sections and described in detail elsewhere (12). The performance of Ethiopia in reducing the burden of HIV/AIDS and reversing this epidemic was remarkable particularly since 2000 (12). Several factors could have helped Ethiopia to achieve the MDG targets. The strong government leadership and political commitment in designing and implementing primary healthcare driven health services could have helped the country to achieve most of the MDG targets (23). Ethiopia has also implemented an innovative community-based health service delivery called Health Extension Program (HEP) since 2003 (23). Salaried and trained female Health Extension Workers (HEW) are involved in the HEP to give basic health package within the community. The HEW uses family folder at Kebele (lowest administrative unit) level to monitor the health service delivery and health status of the population. The HEP and the Family Folder have been instrumental to make health services accessible to the poor (20, 23–25). The HEP could be one of the contributors of an improved annual rate of change for the mortality rates of HIV/AIDS (11%) between 2003 and 2015 (26). The expansion of antiretroviral treatment (ART) free of charge since 2003 could be instrumental to reduce the incidence and mortality rates of HIV/AIDS (27). As a result of government commitment and direction, ART delivery has been scaled down to the primary healthcare unit to ensure better coverage and utilization for the poor (28). Some studies show that mortality decline among individuals living with HIV/AIDS in Ethiopia is consistent with ART coverage and uptake (29,30). However, the ART coverage in adults (59%) and children (23%) is still very low in Ethiopia, which leads vulnerable populations to premature mortality (5,31). The contribution of development partners to fight HIV/AIDS and TB (PEPFAR) has been also vital in fighting HIV/AIDS and TB in Ethiopia. The government has used flexible modalities of One-plan, One-budget and One-Report concept and effectively utilized the funding to scale up interventions towards HIV/AIDS and TB(32). Donors' funding could decline during the coming years, and Ethiopia should strengthen the low-cost and high impact HEP-based interventions to sustain progress (11,33). Despite considerable progress in the past, Ethiopia has now several challenges in achieving the 90-90-90 global targets of HIV/AIDS by 2020(5). Based on these global targets, 90% of the population should know their HIV status. Similarly, 90% of those who know their HIV should be treated and 90% of the treated should be virally suppressed by 2020 (5). There are several barriers for Ethiopia to achieve these targets in the coming years. TB/HIV co-infection and its impact on stigma and mental health problems could also be a big hurdle for the HIV/AIDS control program (34,35). In the rural part of the country, stigma and prejudices are still widespread which needs tailored intervention (36). Continuous community mobilization, stigma reduction and care and support services have been vital for increasing utilization of ART services and improving retention in care that helps to reduce early mortality due to HIV/AIDS in Ethiopia (27). On the other hand, the level of funding for HIV/AIDS has declined recently that may affect the momentum of HIV interventions in Ethiopia. This study is based on the GBD 2016 that uses comprehensive data sources and rigorous analysis. However, the study has some limitations. First, the use of verbal autopsy (VA) data in morality estimation may introduce misclassification bias. Use of published articles could introduce publication bias since unfavorable findings may not be published. In conclusion, Ethiopia has achieved most of the MDG targets related to HIV/AIDS. However, the decline in HIV/AIDS mortality rate has been slow. Ethiopia should strengthen HIV case detection and treatment programs at community level through the HEP to reduce the burden of these diseases during the SDG-era.
  21 in total

1.  Uptake of provider-initiated counselling and testing among tuberculosis suspects, Ethiopia.

Authors:  A Deribew; N Negussu; W Kassahun; L Apers; R Colebunders
Journal:  Int J Tuberc Lung Dis       Date:  2010-11       Impact factor: 2.373

2.  Countdown to 2015: comparing progress towards the achievement of the health Millennium Development Goals in Ethiopia and other sub-Saharan African countries.

Authors:  Sandro Accorsi; Nejmudin Kedir Bilal; Pasquale Farese; Vincenzo Racalbuto
Journal:  Trans R Soc Trop Med Hyg       Date:  2010-01-27       Impact factor: 2.184

3.  Extension workers drive Ethiopia's primary health care.

Authors:  Wairagala Wakabi
Journal:  Lancet       Date:  2008-09-13       Impact factor: 79.321

Review 4.  HIV/AIDS in Ethiopia: where is the epidemic heading?

Authors:  W Hladik; I Shabbir; A Jelaludin; A Woldu; M Tsehaynesh; W Tadesse
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

5.  Prejudice and misconceptions about tuberculosis and HIV in rural and urban communities in Ethiopia: a challenge for the TB/HIV control program.

Authors:  Amare Deribew; Gemeda Abebe; Ludwig Apers; Chali Jira; Markos Tesfaye; Jafar Shifa; Alemseged Abdisa; Kifle Woldemichael; Fetene Deribie; Mesele Bezabih; Abraham Aseffa; Robert Colebunders
Journal:  BMC Public Health       Date:  2010-07-06       Impact factor: 3.295

6.  The synergy between TB and HIV co-infection on perceived stigma in Ethiopia.

Authors:  Amare Deribew; Yohannes Hailemichael; Markos Tesfaye; Dejene Desalegn; Ajeme Wogi; Shallo Daba
Journal:  BMC Res Notes       Date:  2010-10-04

7.  The public health approach to antiretroviral treatment (ART) service scale-up in Ethiopia: the first two years of free ART, 2005-2007.

Authors:  Yibeltal Assefa; Helmut Kloos
Journal:  Ethiop Med J       Date:  2008-10

8.  Steep declines in population-level AIDS mortality following the introduction of antiretroviral therapy in Addis Ababa, Ethiopia.

Authors:  Georges Reniers; Tekebash Araya; Gail Davey; Nico Nagelkerke; Yemane Berhane; Roel Coutinho; Eduard J Sanders
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

9.  Modeling causes of death: an integrated approach using CODEm.

Authors:  Kyle J Foreman; Rafael Lozano; Alan D Lopez; Christopher Jl Murray
Journal:  Popul Health Metr       Date:  2012-01-06

10.  The effect of antiretroviral therapy provision on all-cause, AIDS and non-AIDS mortality at the population level--a comparative analysis of data from four settings in Southern and East Africa.

Authors:  Sian Floyd; Milly Marston; Kathy Baisley; Alison Wringe; Kobus Herbst; Menard Chihana; Ivan Kasamba; Till Bärnighausen; Mark Urassa; Neil French; Jim Todd; Basia Zaba
Journal:  Trop Med Int Health       Date:  2012-08       Impact factor: 2.622

View more
  17 in total

1.  Does Women's Autonomy Matter on Attitude Towards Condom Use in Reducing Risk for HIV Infection Among Married Women in Ethiopia?

Authors:  Mohammed Ahmed; Abdu Seid
Journal:  HIV AIDS (Auckl)       Date:  2020-09-30

2.  Magnitude of non-adherence to antiretroviral therapy and associated factors among adult people living with HIV/AIDS in Benishangul-Gumuz Regional State, Ethiopia.

Authors:  Fikadu Tadesse Nigusso; Azwihangwisi Helen Mavhandu-Mudzusi
Journal:  PeerJ       Date:  2020-08-11       Impact factor: 2.984

3.  Mortality and its association with CD4 cell count and hemoglobin level among children on antiretroviral therapy in Ethiopia: a systematic review and meta-analysis.

Authors:  Chalachew Adugna Wubneh; Getaneh Mulualem Belay
Journal:  Trop Med Health       Date:  2020-09-21

Review 4.  Chronic Immune Activation in TB/HIV Co-infection.

Authors:  Riti Sharan; Allison N Bucşan; Shashank Ganatra; Mirko Paiardini; Mahesh Mohan; Smriti Mehra; Shabaana A Khader; Deepak Kaushal
Journal:  Trends Microbiol       Date:  2020-04-22       Impact factor: 17.079

5.  The Prevalence of HIV-Positive Infants Born to HIV-Positive Mothers Attended at the University of Gondar Specialized Hospital Anti-Retroviral Therapy Services, Northwest Ethiopia, 2018.

Authors:  Destaye Guadie Kassie; Worknesh Akanaw Bogale; Ayenew Addisu
Journal:  HIV AIDS (Auckl)       Date:  2020-03-26

6.  Survival and Predictors of Mortality Among HIV Positive Adult Patients on Highly Active Antiretroviral Therapy in Public Hospitals of Kambata Tambaro Zone, Southern Ethiopia: A Retrospective Cohort Study.

Authors:  Wondimu Abuto; Admas Abera; Tesfaye Gobena; Tariku Dingeta; Melese Markos
Journal:  HIV AIDS (Auckl)       Date:  2021-03-12

7.  Predictors of Survival Time Among HIV-Infected Adults After Initiating Anti-Retroviral Therapy in Kombolcha Town: A 5-Year Retrospective Cohort Study.

Authors:  Muhammed Siraj; Sisay Gedamu; Belachew Tegegne
Journal:  HIV AIDS (Auckl)       Date:  2022-04-16

8.  HIV/AIDS research in Africa and the Middle East: participation and equity in North-South collaborations and relationships.

Authors:  Gregorio González-Alcaide; Marouane Menchi-Elanzi; Edy Nacarapa; José-Manuel Ramos-Rincón
Journal:  Global Health       Date:  2020-09-17       Impact factor: 4.185

9.  Progress towards the 2020 fast track HIV/AIDS reduction targets across ages in Ethiopia as compared to neighboring countries using global burden of diseases 2017 data.

Authors:  Alemnesh H Mirkuzie; Solomon Ali; Ebba Abate; Asnake Worku; Awoke Misganaw
Journal:  BMC Public Health       Date:  2021-02-04       Impact factor: 3.295

10.  Study on Prediction Model of HIV Incidence Based on GRU Neural Network Optimized by MHPSO.

Authors:  Xiaoming Li; Xianghui Xu; Jie Wang; Jing Li; Sheng Qin; Juxiang Yuan
Journal:  IEEE Access       Date:  2020-03-10       Impact factor: 3.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.